- Court of Justice: Trade mark use in clinical trials, no bar to non-use revocation
- Clinical trials and genuine use
- Clinical trials as grounds for non-use
- Next steps?
Life Sciences analysis: This month, the Court of Justice of the European Union addressed a case of particular interest for pharmaceutical companies that are in the process of developing a new product. As marketing authorisations for the product may follow different timelines across jurisdictions, applicants should carefully consider the timing of trade mark applications on account of the regulatory and commercial strategies for the product in order to reduce the risk of revocation for non-use.
Sign in or take a trial to read the full analysis.
To continue reading this news article, as well as thousands of others like it, sign in to LexisPSL or register for a free trial